Consistent with the metastatic HRpHER2n-focused MONALEESA clinical trial30, we did not find evidence of difference in ESR1 mutation frequency between the PAM50 subtypes in our primary breast cancer cohorts that may explain the lower ESR1 expression and the obviously poorer response to endocrine therapy in HER2E tumors. The gene discussed is ESR1; the disease is breast carcinoma.